Journal
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
Volume -, Issue -, Pages -Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10928-023-09867-7
Keywords
Physiologically-based pharmacokinetics (PBPK); Drug-drug interaction (DDI); Enzalutamide; Apixaban; Rivaroxaban; P-glycoprotein (P-gp)
Categories
Ask authors/readers for more resources
Enzalutamide strongly induces CYP3A4 and has both induction and inhibition effects on P-gp. A DDI study with digoxin suggested weak inhibitory effect of enzalutamide on P-gp substrates. The net effect of enzalutamide on apixaban and rivaroxaban plasma exposures, which are dual substrates of CYP3A4 and P-gp, was investigated using PBPK analysis. The simulation results showed a decrease in AUC for both drugs when co-administered with enzalutamide.
Enzalutamide is known to strongly induce cytochrome P450 3A4 (CYP3A4). Furthermore, enzalutamide showed induction and inhibition of P-glycoprotein (P-gp) in in vitro studies. A clinical drug-drug interaction (DDI) study between enzalutamide and digoxin, a typical P-gp substrate, suggested enzalutamide has weak inhibitory effect on P-gp substrates. Direct oral anticoagulants (DOACs), such as apixaban and rivaroxaban, are dual substrates of CYP3A4 and P-gp, and hence it is recommended to avoid co-administration of these DOACs with combined P-gp and strong CYP3A inducers. Enzalutamide's net effect on P-gp and CYP3A for apixaban and rivaroxaban plasma exposures is of interest to physicians who treat patients for venous thromboembolism with prostate cancer. Accordingly, a physiologically-based pharmacokinetic (PBPK) analysis was performed to predict the magnitude of DDI on apixaban and rivaroxaban exposures in the presence of 160 mg once-daily dosing of enzalutamide. The PBPK models of enzalutamide and M2, a major metabolite of enzalutamide which also has potential to induce CYP3A and P-gp and inhibit P-gp, were developed and verified as perpetrators of CYP3A-and P-gp-mediated interaction. Simulation results predicted a 31% decrease in AUC and no change in C-max for apixaban and a 45% decrease in AUC and a 25% decrease in C-max for rivaroxaban when 160 mg multiple doses of enzalutamide were co-administered. In summary, enzalutamide is considered to decrease apixaban and rivaroxaban exposure through the combined effects of CYP3A induction and net P-gp inhibition. Concurrent use of these drugs warrants careful monitoring for efficacy and safety.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available